Episodic Migraine Clinical Trial
— DSTOfficial title:
The Effect of Daylight Saving Time Transitions on Sleep and Migraine Headaches.
NCT number | NCT05742191 |
Other study ID # | 1969211 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 6, 2023 |
Est. completion date | June 1, 2023 |
A prospective study that investigates the impact of circadian rhythm disturbances due to daylight saving time transitions on migraine patients. The Primary aim is to investigate the impact of springtime DST (March 12 2023 at 2 AM on Sunday) on sleep metrics in patients with migraine headaches. Secondary aim is to examine the association between incidence of migraine headaches and sleep metrics with time transitions. Participants will be provided with a Withings non-wearable/contactless sleep tracker, which will be placed under the mattress for a period of 4 weeks (2 weeks before and 2 weeks after) during daylight saving time transition in March, 2023. Withings Health Mate app will be downloaded to the participant's smartphone to collect Sleep Data. Headache diaries will be provided to log the details of the migraines during the study period. Morningness - eveningness questionnaire (MEQ) will be used to categorize subjects on the chronotype spectrum.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 1, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 years and older 2. Episodic migraine diagnosis based on ICHD 3 criteria 3. Subjects with smart phone who can download and use the Health Mate app available on iOS14 and higher and Android 8.0 and higher (Cannot be set up from a computer) 4. Subjects that can commit to sleep on the same bed/mattress every night during the study period 5. Subjects that can commit not to use sleep aids (either prescription or over the counter sleep aids) or sedating medications (sedating anti-depressants, benzodiazepines, anti-histamines, anti-psychotics or gabapentinoids) that assist with sleep onset during the study period. Exclusion Criteria: 1. Patients who do not meet ICHD-3 diagnostic criteria for migraine 2. Patients with migraine diagnosis who are suspected or confirmed to have active medication overuse headaches during the study period. 3. Patients who regularly use sleep aids (either prescription or over the counter sleep aids) or sedating medications (sedating anti-depressants, benzodiazepines, anti-histamines, anti-psychotics or gabapentinoids) to assist with sleep onset. 4. Participants who are planning to initiate new treatment for sleep disorders during the study period. 5. Subjects who participate in shift work. |
Country | Name | City | State |
---|---|---|---|
United States | OSF HealthCare Saint Francis Medical Center | Peoria | Illinois |
Lead Sponsor | Collaborator |
---|---|
OSF Healthcare System |
United States,
Bertisch SM, Li W, Buettner C, Mostofsky E, Rueschman M, Kaplan ER, Fung J, Huntington S, Murphy T, Stead C, Burstein R, Redline S, Mittleman MA. Nightly sleep duration, fragmentation, and quality and daily risk of migraine. Neurology. 2020 Feb 4;94(5):e4 — View Citation
Chudow JJ, Dreyfus I, Zaremski L, Mazori AY, Fisher JD, Di Biase L, Romero J, Ferrick KJ, Krumerman A. Changes in atrial fibrillation admissions following daylight saving time transitions. Sleep Med. 2020 May;69:155-158. doi: 10.1016/j.sleep.2020.01.018. — View Citation
Edouard P, Campo D, Bartet P, Yang RY, Bruyneel M, Roisman G, Escourrou P. Validation of the Withings Sleep Analyzer, an under-the-mattress device for the detection of moderate-severe sleep apnea syndrome. J Clin Sleep Med. 2021 Jun 1;17(6):1217-1227. doi — View Citation
Fritz J, VoPham T, Wright KP Jr, Vetter C. A Chronobiological Evaluation of the Acute Effects of Daylight Saving Time on Traffic Accident Risk. Curr Biol. 2020 Feb 24;30(4):729-735.e2. doi: 10.1016/j.cub.2019.12.045. Epub 2020 Jan 30. — View Citation
Haque B, Rahman KM, Hoque A, Hasan AT, Chowdhury RN, Khan SU, Alam MB, Habib M, Mohammad QD. Precipitating and relieving factors of migraine versus tension type headache. BMC Neurol. 2012 Aug 25;12:82. doi: 10.1186/1471-2377-12-82. — View Citation
Hook J, Smith K, Andrew E, Ball J, Nehme Z. Daylight savings time transitions and risk of out-of-hospital cardiac arrest: An interrupted time series analysis. Resuscitation. 2021 Nov;168:84-90. doi: 10.1016/j.resuscitation.2021.09.021. Epub 2021 Sep 24. — View Citation
Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. — View Citation
Kantermann T, Juda M, Merrow M, Roenneberg T. The human circadian clock's seasonal adjustment is disrupted by daylight saving time. Curr Biol. 2007 Nov 20;17(22):1996-2000. doi: 10.1016/j.cub.2007.10.025. Epub 2007 Oct 25. — View Citation
Lahti TA, Leppamaki S, Lonnqvist J, Partonen T. Transition to daylight saving time reduces sleep duration plus sleep efficiency of the deprived sleep. Neurosci Lett. 2006 Oct 9;406(3):174-7. doi: 10.1016/j.neulet.2006.07.024. Epub 2006 Aug 22. — View Citation
Mollaoglu M. Trigger factors in migraine patients. J Health Psychol. 2013 Jul;18(7):984-94. doi: 10.1177/1359105312446773. Epub 2012 Oct 26. — View Citation
Negro A, Seidel JL, Houben T, Yu ES, Rosen I, Arreguin AJ, Yalcin N, Shorser-Gentile L, Pearlman L, Sadhegian H, Vetrivelan R, Chamberlin NL, Ayata C, Martelletti P, Moskowitz MA, Eikermann-Haerter K. Acute sleep deprivation enhances susceptibility to the — View Citation
Prats-Uribe A, Tobias A, Prieto-Alhambra D. Excess Risk of Fatal Road Traffic Accidents on the Day of Daylight Saving Time Change. Epidemiology. 2018 Sep;29(5):e44-e45. doi: 10.1097/EDE.0000000000000865. No abstract available. — View Citation
Rishi MA, Ahmed O, Barrantes Perez JH, Berneking M, Dombrowsky J, Flynn-Evans EE, Santiago V, Sullivan SS, Upender R, Yuen K, Abbasi-Feinberg F, Aurora RN, Carden KA, Kirsch DB, Kristo DA, Malhotra RK, Martin JL, Olson EJ, Ramar K, Rosen CL, Rowley JA, Sh — View Citation
Roenneberg T, Winnebeck EC, Klerman EB. Daylight Saving Time and Artificial Time Zones - A Battle Between Biological and Social Times. Front Physiol. 2019 Aug 7;10:944. doi: 10.3389/fphys.2019.00944. eCollection 2019. Erratum In: Front Physiol. 2019 Sep 1 — View Citation
Sipila JO, Ruuskanen JO, Rautava P, Kyto V. Changes in ischemic stroke occurrence following daylight saving time transitions. Sleep Med. 2016 Nov-Dec;27-28:20-24. doi: 10.1016/j.sleep.2016.10.009. Epub 2016 Nov 2. — View Citation
Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep. 2007 Apr;30(4):494-505. doi: 10.1093/sleep/30.4.494. — View Citation
Song TJ, Yun CH, Cho SJ, Kim WJ, Yang KI, Chu MK. Short sleep duration and poor sleep quality among migraineurs: A population-based study. Cephalalgia. 2018 Apr;38(5):855-864. doi: 10.1177/0333102417716936. Epub 2017 Jun 22. — View Citation
Strazisar BG, Strazisar L. Daylight Saving Time: Pros and Cons. Sleep Med Clin. 2021 Sep;16(3):523-531. doi: 10.1016/j.jsmc.2021.05.007. Epub 2021 Jul 2. — View Citation
Tyler J, Fang Y, Goldstein C, Forger D, Sen S, Burmeister M. Genomic heterogeneity affects the response to Daylight Saving Time. Sci Rep. 2021 Jul 20;11(1):14792. doi: 10.1038/s41598-021-94459-z. — View Citation
Yadav RK, Kalita J, Misra UK. A study of triggers of migraine in India. Pain Med. 2010 Jan;11(1):44-7. doi: 10.1111/j.1526-4637.2009.00725.x. Epub 2009 Sep 29. — View Citation
* Note: There are 20 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Circadian rhythm disturbances and alteration of total sleep time and sleep efficiency | To investigate the impact of springtime DST (March 12 2023 at 2 AM on Sunday) on sleep metrics in patients with migraine headaches. | 4 weeks | |
Secondary | Migraine Headaches | To examine the association between incidence of migraine headaches and sleep metrics with time transitions. | 4 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
Completed |
NCT00719134 -
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
|
Phase 4 | |
Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
Active, not recruiting |
NCT05028569 -
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
|
Phase 3 | |
Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 |